Peri‐operative modulation of cellular immunity in patients with colorectal cancer

The peri‐operalive cellular immune response is depressed in patients with gastrointestinal cancer, a factor which may facilitate maligtiant dissemination. We have investigated the effects of perioperative rIL‐2 and a combination of rlL‐2 and interferon‐alpha (IFN‐α) on both peripheral blood lymphocyte function and number in patients undergoing surgical resection for colorectal cancer. Fifty‐two patients were randomly allocated to either control, rIL‐2 or rIL‐2 with IFN‐α treatment arms. In vitro studies were performed pre‐operatively and on post‐operative days I, 4, 7 and 10. Natural ikller (NK) and lymphokine‐activated killer (LAK) cell function were profoundly depressed in control patients (P < 0.001; P < 0.001), an effect abrogated in both treatment groups; indeed NK function was augmented in the rIL‐2 and IFN‐α group on the first post‐operative day in association with an increase in the percentage of cells expressing CD16 and CD56 (P < 0.01). Flow cytometric analysis of lymphocyte subsets in the control group was unremarkable, except for an early post‐operative fall in numbers of lymphocytes. Treatment with either rIL‐2 or rIL‐2 and IFN‐α produced an initial profound reduction in T lymphocyte numbers, followed by a ‘rebound’ lymphocytosis of activated CD3+ T cells, as demonstrated by a significant increase in co‐expression of CD25, CD38, and CD45RO. No significant differences were observed between either of the treatment groups. Adjuvant immunotherapy affects peri‐operative anti‐tumour immune responses, and this may influence long term outcome in patients undergoing surgery for gastrointestinal cancer.

[1]  J. Primrose,et al.  Perioperative immunotherapy with recombinant interleukin 2 in patients undergoing surgery for colorectal cancer. , 1992, Cancer research.

[2]  P. Guillou,et al.  Simplified quantitation of cytotoxicity by integration of specific lysis against effector cell concentration at a constant target cell concentration and measuring the area under the curve. , 1991, Journal of immunological methods.

[3]  Timothy A. Springer,et al.  Adhesion receptors of the immune system , 1990, Nature.

[4]  H. Kirchner,et al.  Home therapy with recombinant interleukin-2 and interferon-α2b in advanced human malignancies , 1990, The Lancet.

[5]  T R Fleming,et al.  Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. , 1990, The New England journal of medicine.

[6]  J. Sosman,et al.  In vivo activation of lymphokine-activated killer activity with interleukin-2: prospects for combination therapies. , 1990, Seminars in oncology.

[7]  E. Borden,et al.  Lymphokines and cytokines as cancer treatment.Immunotherapy realized , 1990, Cancer.

[8]  P. Guillou,et al.  Effects of low dose perioperative interferon on the surgically induced suppression of antitumour immune responses , 1988, The British journal of surgery.

[9]  Kendall A. Smith,et al.  Interleukin-2: inception, impact, and implications. , 1988, Science.

[10]  M. Cazzola,et al.  Interferons as biologic modulators of hematopoietic cell proliferation and differentiation. , 1988, Haematologica.

[11]  R. Fisher,et al.  In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2. , 1988, Journal of immunology.

[12]  J. Dutcher,et al.  Phase II Trial of Recombinant Alpha‐2b‐Interferon and Low‐Dose Cyclophosphamide in Advanced Melanoma and Renal Cell Carcinoma , 1988, American journal of clinical oncology.

[13]  N. Saijo,et al.  In vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors. , 1988, Cancer research.

[14]  S. Rosenberg,et al.  Immunotherapy of a murine tumor with interleukin 2. Increased sensitivity after MHC class I gene transfection , 1987, The Journal of experimental medicine.

[15]  J. Thompson,et al.  Recombinant interleukin 2 toxicity, pharmacokinetics, and immunomodulatory effects in a phase I trial. , 1987, Cancer research.

[16]  P. Bell,et al.  Five year results of a randomized trial of adjuvant 5‐fluorouracil and levamisole in colorectal cancer , 1987, The British journal of surgery.

[17]  M. Pescatori,et al.  Outcome of colorectal cancer , 1987, The British journal of surgery.

[18]  W. M. Linehan,et al.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. , 1987, The New England journal of medicine.

[19]  G. Marshall,et al.  Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. , 1987, The New England journal of medicine.

[20]  A. Chang,et al.  High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. , 1986, JAMA.

[21]  C. McArdle,et al.  Occult hepatic metastases in colorectal carcinoma , 1986, The British journal of surgery.

[22]  J. Laszlo,et al.  Interferon therapy in cancer: from imaginon to interferon. , 1986, Cancer research.

[23]  S. Emoto,et al.  Do operations facilitate tumor growth? An experimental model in rats. , 1986, Surgery.

[24]  P. Guillou,et al.  Decreased interleukin−2 production in patients with gastrointestinal cancer , 1986, The British journal of surgery.

[25]  Y. Miyauchi,et al.  Prevention of growth of metastases in rat liver by perioperative immunoactivation. , 1986, Cancer research.

[26]  B. Shenton,et al.  The influence of surgical operations on components of the human immune system , 1985, The British journal of surgery.

[27]  G. Trinchieri,et al.  Immune interferon: a pleiotropic lymphokine with multiple effects. , 1985, Immunology today.

[28]  S. Rosenberg,et al.  Lymphokine-activated killer cell phenomenon. Lysis of natural killer- resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes , 1982, The Journal of experimental medicine.

[29]  Kendall A. Smith,et al.  T cell growth factor: parameters of production and a quantitative microassay for activity. , 1978, Journal of immunology.

[30]  J. Lundy,et al.  Halothane, surgery, immunosuppression and artificial pulmonary metastases , 1978 .

[31]  J. Ortaldo,et al.  Cytotoxic reactivity of human lymphocytes cultured in vitro. , 1977, Journal of immunology.

[32]  R. Simmons,et al.  Immunodepression after major surgery in normal patients. , 1975, Surgery.

[33]  J. Griffiths,et al.  CIRCULATING CANCER CELLS DURING EXCISION OF CARINOMAS OF THE RECTUM AND COLON WITH HIGH LIGATION OF THE INFERIOR MESENTERIC VEIN. , 1965, Surgery, gynecology & obstetrics.

[34]  D. Morton,et al.  Effects of operation on immune response in cancer patients: sequential evaluation of in vitro lymphocyte function. , 1976, Surgery.

[35]  A. Bøyum,et al.  Separation of leukocytes from blood and bone marrow. Introduction. , 1968 .